TLR4 and neoplasm: Mice transferred with splenocytes from previous OAd-MSC WT and of OAd-MSC TLR4−/− groups showed a trend toward decreased tumor growth compared to those treated with splenocytes from PBS group (Supplementary Fig. S2E), which confirmed the presence of antitumor immunity triggered by the cell-based virotherapy.